Best Life Sciences Platforms and Tools Companies in New York, United States

Developer of pipetting robot for lab automation. The company's product OT-2 personal pipetting robot uses manual micro-pipettes to transfer fluids and automates the repetitive benchwork associated with lab activities. It also has scalable hardware and software and is developed in an open-source manner.

Funding rounds

• Nov 2025Series C$20.1M
• Sep 2021Series C$200M
• Aug 2020Series B$20.6M
• Nov 2019Seed$2.2M

Founders & team

James AtwoodCEOJonathan Brennan-BadalCEO

Investors

HAX, Khosla Ventures, Y Combinator, Lerer Hippeau, SoftBank Group, Sands Capital

Tech stack

AlgoliaAlpine.JsAmazon S3Amazon Web ServicesApple Icloud MailBigcommerce

Developer of a microfluidic-based automated device used for sample preparation. The company uses its patented lab-on-chip microfluidic technology for the processing of the cellular sample. It has applications in long-read DNA sequencing, multi-omic analysis, and pathogen isolation.

Funding rounds

• Mar 2026Seed$750K
• Jul 2023Grant (prize money)$174.7K
• Feb 2022Seed$2.2M
• Oct 2021Seed$250K

Founders & team

Harvey TianCo-Founder & CEOAdam BisogniCo-Founder

Investors

IndieBio, 2048 Ventures, SOSV, Whitecap Venture Partners, CRCM Ventures, Ataraxia

Developer of live-attenuated viral vaccines using proprietary SAVE technology. The SAVE platform relies on synthetic biology and re-design of the target virus' entire genome to yield a vaccine strain. All pipeline vaccines are currently in preclinical stages targeting seasonal influenza, dengue virus (DEV), respiratory syncytial virus (RCV), and pandemic influenza.

Medical device incubator creating innovative solutions for cardiology, pulmonary, and renal patients. This incubator specializes in medical device innovation, focusing on unmet needs in cardiac, pulmonary, and renal care. They invent and translate healthcare solutions into impactful devices, offering hope to patients with limited treatment options. With a proven track record, they launch companies focused on these critical areas, driving advancements in medical technology. Their expertise lies in medical device incubation, venture capital, clinical research, ideation, intellectual property, and start-ups, fostering a pipeline of groundbreaking medical solutions. They aim to expand their portfolio and launch new ventures regularly, contributing to the evolution of healthcare.

Developer of chiral separation technology for safer, faster drug production. The technology aims to produce purer active pharmaceutical ingredients. It focuses on shortening production timelines and reducing drug side effects. The company's technology seeks to deliver higher purity with less waste. It strives to provide a manufacturing system built for long-term use.

Funding rounds

• Oct 2025Seed$3.1M

Founders & team

Arielle GabalskiFounder

AptaMatrix is a biotechnology company focused on developing next-generation technology (High Throughput Screening of Aptamers (HTSA)) based on new tools to accelerate the aptamer's discovery. The company is developing an aptamer-based platform "AlloSwitch" sensor technology that can facilitate drug discovery and rapid detection of chemical and biological analytes. The company claims that using their AptaMatirx's proprietary workflow, the time required for aptamer discovery can be reduced to 2 weeks which can be further reduced to 3 days in the future. In addition, the company provides consulting and technical support to both academic and commercial deep-sequencing projects.

Funding rounds

• Apr 2025Grant (prize money)$2M
• Sep 2020Grant (prize money)$2M
• Jul 2016Grant (prize money)$176.8K
• Sep 2010Grant (prize money)$1.1M

Founders & team

Philip BorerCo-Founder & PresidentBruce HudsonCo-Founder

Investors

HHS, NIH SBIR/STTR

Tech stack

Apache Http Server

Supercritical CO2 sterilization technology and services for medical and life sciences. The company provides environmentally friendly sterilization solutions, offering an alternative to EO with broader compatibility, including biologics. They cater to industries like medical devices, regenerative medicine, combination products, biotherapeutics, APIs, life sciences R&D tools, and additive manufacturing. Offerings include sterilization equipment, sterilization services, and supercritical CO2 technology. They focus on advancing product safety and patient outcomes through novel supercritical CO2 solutions, providing a safer, gentler, and more effective terminal sterilization process. They serve tissue banking, regenerative medicine, and medical device markets with equipment, additives, and processes, performing contract research on applications of scCO2 across a broad range of materials.

Funding rounds

• Mar 2025Grant (prize money)$2M
• Jul 2022Grant (prize money)$2M
• Jul 2015Grant (prize money)$1.2M
• Feb 2015Grant (prize money)$147.3K

Founders & team

David Burnspresident and ceo

Investors

HHS, KensaGroup, BRV

Tech stack

Apache Http ServerBootstrapContact Form 7Core-JsElementorElementor Header & Footer Builder

Discovering novel therapeutics for neurological and metabolic diseases. The company focuses on addressing significant health challenges by developing effective and well-tolerated agents. Utilizing the Klarity Platform, scientists investigate medicines targeting metabolism, including type 2 diabetes and obesity, and neurological disorders like migraine and pain. The company pursues innovative approaches to medicine discovery, integrating technologies for differentiated therapeutic development. With a team of scientists and drug developers, the company fosters a culture of innovation and collaboration to advance human health. The company operates in the pharmaceutical and biotechnology sectors, focusing on research and development to create solutions for unmet medical needs. The company's work has a direct social impact by aiming to improve the lives of patients and families affected by these diseases.

Funding rounds

• May 2023Grant (prize money)$8.2M
• Feb 2022Series D$236M
• Mar 2020Series C$112M
• Dec 2018Series B$21M

Founders & team

Charles ZukerCo-FounderRichard AxelCo-FounderTom ManiatisCo-Founder

Investors

Illumina Ventures, Alexandria, The Column Group, Lux Capital, Polaris Partners, Two Sigma Ventures

Tech stack

WordpressMysqlMariadbPhpVarnishYoast Seo

Nanomembrane technology for life science, material science, and microplastic analysis. They develop and manufacture silicon nanomembranes and BioMEMS technologies. Their products include porous membrane chips, TEM grids, X-Ray windows, and particle filters. These products enable superior data generation and analysis in transmission electron microscopy, X-ray microscopy, particle analysis, cell culture, nanofiltration, and microplastic analysis. They offer custom fabrication services to meet unique application needs. The company is ISO certified, demonstrating a commitment to quality. They serve researchers in life sciences and materials science, providing tools for nanoscale specimen analysis. They are a bioMEMS company advancing research and innovation in healthcare and beyond. They offer resources like publications, application notes, and technical data sheets. They are a nanotechnology company in the USA.

Funding rounds

• Jan 2025Grant (prize money)$1.4M
• May 2020Grant (prize money)$1.9M
• Sep 2019Grant (prize money)$1.4M
• Mar 2018Grant (prize money)$225K

Founders & team

Paul ThenChief Executive Officer

Investors

HHS, NextCorps

TEZCAT is developing therapies for cancer treatment. It is focusing on colorectal cancer and its technology block cancer processes such as nutrient scavenging via macropinocytosis and YAPL signaling.

Funding rounds

• May 2025Grant (prize money)$2.2M

Founders & team

Andrew HauserCo-Founder & COOCraig RamirezCo-Founder & CSO

Investors

HHS, Design Technologies

Biotech pioneering treatments for Sanfilippo Syndrome, an ultra-rare genetic disease. Focused on developing therapies for this devastating condition, the company is dedicated to improving the lives of affected children and their families. They conduct natural history studies and preclinical research to advance potential treatments for various subtypes of Sanfilippo Syndrome. The company collaborates with academic labs and leverages funding to drive innovation in this challenging therapeutic area. Their commitment extends to providing patient and physician resources, fostering a supportive community, and raising awareness about Sanfilippo Syndrome. They are working towards creating a future where individuals affected by this disease can live fuller, healthier lives.

Developer of universal, nondestructive body fluid identification methods for forensic science. This technology utilizes laser spectroscopy and advanced statistics to streamline forensic analysis of biological stains. The methods allow for the detection, identification, and analysis of major body fluids. Development was supported by grants from the National Institute of Justice and the National Science Foundation, focusing on commercialization of a patented universal method. The technology is intended for use in forensic laboratories and law enforcement agencies.

Funding rounds

• Apr 2025Grant (prize money)$1000K
• May 2021Grant (prize money)$256K

Founders & team

Igor LednevCofounder and CTO

Investors

National Science Foundation